RxDoctor Payments Data

Charles Furr, PA

Physician Assistant · Ruston, LANPI 1295988517

Payments from drug & device makers

$5,113in general payments, 2019–2025

Across 313 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$744
  • Takeda Pharmaceuticals U.S.A., Inc.$579
  • Pfizer$399
  • Novo Nordisk$366
  • Bayer$354
  • Amgen$313
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,06599%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,113 in reported general payments places this provider in the 90th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,453
Medicare patients
180
Services billed
2,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$33,547
JardianceEmpagliflozin49$32,045
OzempicSemaglutide29$27,364
EliquisApixaban42$22,952
FarxigaDapagliflozin Propanediol28$20,382
TrulicityDulaglutide18$18,840
MyrbetriqMirabegron38$17,069
XareltoRivaroxaban20$14,025
Xigduo XrDapaglifloz Propaned/Metformin20$11,724
TrintellixVortioxetine Hydrobromide23$10,966
Breo ElliptaFluticasone/Vilanterol22$8,332
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$5,911
Gabapentin137$1,830
Omeprazole124$1,696
Pantoprazole Sodium136$1,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$230$52,38740 claims
Boehringer IngelheimJardiance$86$32,04549 claims
Novo NordiskOzempic$366$27,36429 claims
PfizerEliquis$399$22,95242 claims
AstraZenecaFarxiga$178$20,38228 claims
Astellas Pharma US IncMyrbetriq$108$17,06938 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$579$10,96623 claims
GSKBreo Ellipta$106$8,33222 claims
AbbVieSynthroid$744$1,07723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →